Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 15 June 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. While the company continues to face challenges in long-term growth and profitability, recent technical indicators and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance.

Nath Bio-Genes (India) Ltd has been downgraded from a Hold to a Sell rating by MarketsMOJO as of 8 June 2026, reflecting concerns over its stagnant financial performance, weak long-term fundamentals, and consistent underperformance against market benchmarks. Despite a very attractive valuation, the company’s deteriorating financial trends and technical indicators have prompted a cautious stance from analysts.

Nath Bio-Genes (India) Ltd, a micro-cap player in the Other Agricultural Products sector, has seen its investment rating upgraded from Sell to Hold as of 1 June 2026. This change reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite persistent challenges in long-term fundamentals, recent technical signals and valuation metrics have improved sufficiently to warrant a more cautious but optimistic stance.

The 50-day moving average for Nath Bio-Genes (India) Ltd has crossed above the 200-day moving average, signalling a golden cross on 1 Jun 2026. While this technical event often suggests a shift towards bullish momentum, the broader technical and fundamental context presents a more nuanced picture that merits careful analysis.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company's performance and outlook.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Nath Bio-Genes (India) Ltd has reported a flat financial performance for the quarter ended March 2026, signalling a stabilisation after a period of decline. While net sales have shown robust growth, profitability metrics and earnings per share continue to face headwinds, reflecting a complex financial landscape for this micro-cap player in the Other Agricultural Products sector.

Nath Bio-Genes (India) Ltd., a micro-cap agricultural products company with a market capitalisation of ₹330.86 crores, reported a shocking loss of ₹0.01 crores for Q4 FY26, marking a complete reversal from the ₹0.94 crores profit posted in Q4 FY25. The stock plunged 7.87% on May 5, 2026, closing at ₹174.45, as investors reacted to an extraordinary tax charge that exceeded the company's pre-tax profit—a rare accounting anomaly that signals potential earnings quality concerns.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Nath Bio-Genes (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 183.52, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nath Bio-Genes (India) Ltd locked at its upper circuit of 10.53% on 13 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Nath Bio-Genes (India) Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting a nuanced shift in its technical outlook despite persistent fundamental challenges. The micro-cap agricultural products company’s recent performance and valuation metrics have prompted a reassessment across quality, valuation, financial trend, and technical parameters, signalling cautious optimism for investors.

Nath Bio-Genes (India) Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 23 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 04 April 2026, providing investors with the latest insights into the company’s performance and outlook.

For the second consecutive session, Nath Bio-Genes (India) Ltd has succumbed to selling pressure, hitting a fresh 52-week low of Rs 127 on 30 Mar 2026, marking a 5.85% decline over two days amid broader market weakness.

A sharp decline in Nath Bio-Genes (India) Ltd has pushed the stock to a fresh 52-week low of Rs 129.15 on 27 Mar 2026, marking a significant 5% intraday drop and extending the recent downtrend despite a brief two-day rally.